Spruce Biosciences, Inc. (SPRB) Stock Score, Valuation & Financial Research

Spruce Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SPRB

Spruce Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 47.30. These figures are a research snapshot, not a buy or sell recommendation.

What Spruce Biosciences, Inc. does

Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Spruce Biosciences is a late-stage biopharmaceutical company that focuses on developing and commercializing novel therapies for rare neurological disorders. The company currently operates as a clinical-stage entity and does not yet generate revenue from product sales, relying instead on capital raises and strategic financing to fund its research and development activities.

Products and services

  • The company's primary product candidate is tralesinidase alfa enzyme replacement therapy (TA-ERT), which is in development for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB).

Brands and product families

  • TA-ERT — Tralesinidase alfa enzyme replacement therapy, the company's lead investigational product candidate. Source

Customer types

Specialized clinicians and medical specialists treating MPS IIIB.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates. Source

Business strengths to evaluate

  • Experienced management team in drug development and commercialization Source
  • Focus on diseases with well-understood biology and high unmet medical need Source

Business risks and research considerations

  • Dependence on the success of a single product candidate, TA-ERT Source
  • Requirement for significant additional capital to fund operations and clinical trials Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SPRB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 47.30
Market capitalization:
130.18M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -51.35M
Free cash flow:
USD -33.33M
Cash:
USD 96.3M
Total debt:
USD 7.67M
EPS:
USD -40.87

What stands out

  • Free cash flow is USD -33.33M, negative for the stored period.
  • The balance sheet shows USD 96.3M of cash versus USD 7.67M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 88.62M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SPRB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SPRB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SPRB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SPRB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SPRB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SPRB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.